Patents by Inventor Christopher John Stanley
Christopher John Stanley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8603771Abstract: Micro-organisms, including fungi, viruses and bacteria such as Mycobacteria and/or fragments of micro-organisms such as cell wall components present in an aqueous liquid are captured to a solid surface by adding to the liquid a sufficient quantity of a water soluble polymer in the presence of the solid surface to displace the micro-organisms and/or fragments from the liquid to the solid surface. The surface may be provided by a bead. The water soluble polymer may be polyethyleneglycol or polyvinylpyrrolidone.Type: GrantFiled: June 29, 2011Date of Patent: December 10, 2013Assignee: Microsens Medtech LimitedInventors: Christopher John Stanley, Stuart Mark Wilson
-
Publication number: 20130171689Abstract: Micro-organisms, including fungi, viruses and bacteria such as Mycobacteria and/or fragments of micro-organisms such as cell wall components present in an aqueous liquid are captured to a solid surface by adding to the liquid a sufficient quantity of a water soluble polymer in the presence of the solid surface to displace the micro-organisms and/or fragments from the liquid to the solid surface. The surface may be provided by a bead. The water soluble polymer may be polyethyleneglycol or polyvinylpyrrolidone.Type: ApplicationFiled: June 29, 2011Publication date: July 4, 2013Applicant: MICROSENS MEDTECH LIMITEDInventors: Christopher John Stanley, Stuart Mark Wilson
-
Patent number: 8383617Abstract: A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.Type: GrantFiled: January 30, 2008Date of Patent: February 26, 2013Assignee: PAD Pharma LimitedInventors: Stuart Mark Wilson, Christopher John Stanley
-
Publication number: 20100291564Abstract: NAD-dependent ligase is identified as an indicator of micro-organisms in a sample. A method of detecting the presence of an NAD-dependent ligase expressing micro-organism in a sample comprises the steps of: (a) contacting the sample with a nucleic acid molecule which acts as a substrate for NAD-dependent ligase activity in the sample, (b) incubating the thus contacted sample under conditions suitable for NAD-dependent ligase activity; and (c) specifically determining the presence of a ligated nucleic acid molecule resulting from the action of the NAD-dependent ligase on the substrate nucleic acid molecule to indicate the presence of the NAD-dependent ligase expressing micro-organism. The method has a number of applications and kits for carrying out the methods are also provided.Type: ApplicationFiled: July 9, 2008Publication date: November 18, 2010Applicant: MICROSEN MEDTECH LIMITEDInventors: Christopher John Stanley, Stuart Wilson
-
Publication number: 20100143883Abstract: A method for the capture from a sample of micro-organisms having a hydrophobic surface, which method includes contacting the micro-organisms with a capture reagent, which capture reagent has both a hydrophobic character whereby the capture reagent binds the micro-organisms by hydrophobic interaction therewith and a polar character, the capture reagent either being present on a surface and capturing the micro-organisms thereto, or being present in solution, the method then further including capturing the micro-organisms to a surface by binding the capture reagent to the surface by polar interaction between the surface and the capture reagent.Type: ApplicationFiled: November 23, 2007Publication date: June 10, 2010Applicant: Microsens Medtech LimitedInventors: Stuart Mark Wilson, Christopher John Stanley
-
Publication number: 20100035859Abstract: A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.Type: ApplicationFiled: January 30, 2008Publication date: February 11, 2010Applicant: PAD Pharma LimitedInventors: Stuart Mark Wilson, Christopher John Stanley
-
Publication number: 20040259131Abstract: The invention relates to methods of detecting target molecules or the interactions between target molecules based on interactions between proximally-bound nucleic acid tags. Reagent kits for use in such methods are also provided.Type: ApplicationFiled: April 2, 2004Publication date: December 23, 2004Applicant: Iseao Technologies LimitedInventors: Stuart Wilson, Christopher John Stanley
-
Patent number: 6627460Abstract: A novel preparative methodology yields water-soluble, cross-linked conjugates and conjugate complexes that confer an improved sensitivity in immunochemical assays, particularly in the context of lateral flow devices and in determinations of the presence or absence of small amounts of active components present in a liquid sample.Type: GrantFiled: April 5, 2001Date of Patent: September 30, 2003Assignee: Amdex A/SInventors: Allan Otto Fog Lihme, Christopher John Stanley
-
Patent number: 6346378Abstract: A nucleic acid analog comprising a polymeric strand which includes a sequence of ligands bound to a backbone made up of linked backbone moieties, which analog is capable of hybridization to a nucleic acid of complementary sequence, further comprising a chelating moiety capable of binding at least one metal ion by chelation.Type: GrantFiled: May 29, 1998Date of Patent: February 12, 2002Assignee: PNA Diagnostics A/SInventors: Christopher John Stanley, Henrik Orum, Mikkel Jorgensen
-
Publication number: 20010047077Abstract: A nucleic acid analog comprising a polymeric strand which includes a sequence of ligands bound to a backbone made up of linked backbone moieties, which analog is capable of hybridization to a nucleic acid of complementary sequence, further comprising a chelating moiety capable of binding at least one metal ion by chelation.Type: ApplicationFiled: May 29, 1998Publication date: November 29, 2001Inventors: CHRISTOPHER JOHN STANLEY, HENRIK ORUM, MIKKEL JORGENSEN
-
Patent number: 6163714Abstract: An implantable sensor for use in the detection or quantitative measurement of an analyte in subcutaneous fluid, the sensor being biodegradable or hydrolysable in vivo. The sensor incorporates an assay for the analyte, the readout of which is a detectable or measurable optical signal which can, when the sensor is in operation in a subcutaneous location, be interrogated transcutaneously by external optical means.Type: GrantFiled: July 2, 1999Date of Patent: December 19, 2000Assignee: Torsana Diabetes Diagnostics A/SInventors: Christopher John Stanley, Anders Weber
-
Patent number: 5972610Abstract: The present invention relates to the use of nucleic acid analogues in blocking nucleic acid amplification procedures and to diagnostic and analytical techniques based thereon. Also included are kits for use in the conduct of nucleic acid amplification reactions.Type: GrantFiled: October 8, 1997Date of Patent: October 26, 1999Inventors: Ole Buchardt, deceased, by Dorte Buchardt, legal representative, Michael Egholm, Peter Eigil Nielsen, Rolf Henrik Berg, Christopher John Stanley
-
Patent number: 5891625Abstract: Nucleic acid analogues such as peptide-nucleic acids (PNAs) which hybridize strongly to nucleic acids are used to inhibit nucleic acid amplification procedures such as PCR. False positives in subsequent PCR assays are prevented by hybridizing a PNA to PCR amplification products. Assays capable of discriminating between single base mutants are conducted by using a PNA hybridizing to one of the two allelic forms to inhibit a PCR amplification of that form selectively. Asymmetric PCR amplifications are carried out by starting a PCR symmetrically using like quantities of forward and reverse primers, and, once the amplification is established, disabling one primer by hybridizing a PNA thereto.Type: GrantFiled: March 10, 1995Date of Patent: April 6, 1999Inventors: Ole Buchardt, deceased, Michael Egholm, Peter Eigil Nielsen, Rolf Henrik Berg, Christopher John Stanley
-
Patent number: 5861250Abstract: A selected region of a nucleic acid is protected from attach by nuclease by completing to the nucleic acid a nucleic acid analogue of the PNA type. The surviving sequence may be detected in an assay, optionally after amplification. A PCR reaction may be sterilized and its product assayed by protecting a characterizing region of the product by PNA hybridization followed by nuclease degradation of unprotected nucleic acid.Type: GrantFiled: June 6, 1996Date of Patent: January 19, 1999Assignee: PNA Diagnostics A/SInventors: Christopher John Stanley, Henrik Orum, Mikkell Jorgensen, Ole Basboll
-
Patent number: 5843663Abstract: A nucleic acid analog comprising a polymeric strand which includes a sequence of ligands bounds to a backbone made up of linked backbone moieties, which analog is capable of hybridization to a nucleic acid of complementary sequence, further comprising a chelating moiety capable of binding at least one metal ion by chelation.Type: GrantFiled: May 24, 1996Date of Patent: December 1, 1998Assignee: Boehringer Mannheim GmbHInventors: Christopher John Stanley, Henrik Orum, Mikkel Jorgensen
-
Patent number: 5744094Abstract: A sterilizing method includes subjecting material, for example packaging board, to laser UV alone, or substantially simultaneously with laser IR and/or hydrogen peroxide to obtain a synergistic effect between the UV and IR and/or hydrogen peroxide, to render micro-organisms present at said material non-viable.Type: GrantFiled: February 24, 1994Date of Patent: April 28, 1998Assignee: Elopak Systems AGInventors: Helge Bakketun Castberg, Karin Bergmann, Peter John Hyde, Karen Margaret Montgomery Ness, Christopher John Stanley
-
Patent number: RE38525Abstract: An implantable sensor for use in the detection of quantitative measurement of an analyte in subcutaneous fluid, the sensor being biodegradable or hydrolysable in vivo. The sensor incorporates an assay for the analyte, the readout of which is a detectable or measurable optical signal which can, when the sensor is in operation in a subcutaneous location, be interrogated transcutaneously by external optical means.Type: GrantFiled: October 23, 2002Date of Patent: June 8, 2004Assignee: Torsana Diabetes Diagnostics A/SInventors: Christopher John Stanley, Anders Weber